"If you're in biotech, you're already thinking about disaster recovery as a daily exercise. If you're relying on power to fuel biological experiments, you can't afford to be without it for four hours without a back-up plan."
– Will Lewis, president and CEO, Insmed Inc., discussing the impact of Hurricane Sandy on biotechs in the storm zone

"You're not going to see Super Bowl time purchase with this investment. But with middle-of-the-night awakening there's the opportunity to interact with people at the time they're awake."
– Glenn Oclassen, CEO and president, Transcept Pharmaceuticals Inc., commenting on the $19 million commitment by Purdue Pharmaceutical Products LP to purchase a six-month direct-to-consumer advertising program for the insomnia drug Intermezzo (zolpidem tartrate), developed by Transcept

"We did that in a smart way, so that we minimized placebo response and succeeded in suppressing variability. I think we have found a formula for success."
– Acadia Pharmaceuticals Inc. CEO Uli Hacksell on reporting positive Phase III trials with pimavanserin in Parkinson's disease psychosis